Drapalin Pharmaceuticals GmbH officially imports and sells medical cannabis wholesale in Germany. Legality of activity is confirmed by all the necessary certificates, and the quality of pharmaceutical products meets EU GMP standards. The company’s office is located in the Bavarian capital of Munich, and its customers include representatives of the German medical community: medical practitioners, pharmacists and wholesale suppliers.
The products are made from the flowers of the cannabis plant (Cannabis sativa L.), which is grown on the African continent in strict compliance with local laws. Taking medicines containing cannabinoids contributes to the well-being and quality of life of patients, including those with cancer and AIDS. In Germany, the use of medical cannabis for therapeutic purposes has been officially legalized since March 10, 2017. For more information about DRAPALIN Pharmaceuticals GmbH’s products, visit the company’s official website: https://drapalin.de/en/.
Table of Contents
DRAPALIN Pharmaceuticals mission and goals
The company was founded in December 2017. DRAPALIN Pharmaceuticals, as a certified importer and wholesaler of medical cannabis:
- Provides physicians, pharmacists and wholesale retailers through an extensive logistics network with the highest quality pharmaceutical products, fully compliant with German legislation.
- Provides a high level of service and comprehensive information support that meets the standards of the German market.
- Strives to gain a high level of trust from the German medical community and a reputation as a reliable partner.
- He contributes to the well-being of patients in Germany as much as he can.
- Constantly working to improve the medical cannabis market.
- Plans to regularly expand its range of cannabis medicines, including prescription CBD/THC extracts.
- It aims to become a globally oriented company with a vertically integrated structure. This will allow full control over all stages of production and sale of its products – growing, processing, distribution.
The backbone of the team is made up of professionals in the pharmaceutical, legal and economic fields. DRAPALIN, like all of its partners, works in strict compliance with legal regulations, so they have received all the necessary certifications to produce, import and sell medical cannabis.
Who can buy medicines containing cannabinoids
The legalization of medical cannabis for medicinal purposes in Germany officially became a reality on March 10, 2017. On this day, an amendment to the laws regulating the use of narcotic drugs in the medical field entered into force. As a result, new opportunities for the German healthcare system have opened up:
- Hemp flowers and extracts were allowed to be used as medicines for therapeutic measures.
- Any practitioner, other than dentists and veterinarians, has the right to prescribe and prescribe cannabis-based medications to a patient on narcotic prescriptions.
- The cost of cannabinoid-containing medications must be covered by health insurance companies if the patient complies with the requirements of the contract.
DRAPALIN Pharmaceuticals products can be purchased by practitioners and pharmacies directly from the company’s official website. To do this, you need to register in the system and upload your license. The company also cooperates with wholesale suppliers of pharmacological products.
